GTO ID | GTC1374 |
Trial ID |
NCT01281098
|
Disease |
Type 2 Diabetes Mellitus
|
Proliferative Diabetic Retinopathy
|
Type 1 Diabetes Mellitus
|
Altered gene | VEGFA |
Therapeutic/Target gene | Target gene |
Therapy | Aptamer |
Treatment | Macugen|pegaptanib|EYE001 |
Co-treatment | Panretinal Photocoagulation (PRP) |
Phase | Phase2 |
Recruitment status | Completed |
Title | Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR) |
Year | 2010 |
Country | Portugal |
Company sponsor | Association for Innovation and Biomedical Research on Light and Image |
Other ID(s) | CC-02-2009|2009-016760-36 |